JOBEVNE
Jobevne (bevacizumab-nwgd) is a vascular endothelial growth factor inhibitor used to treat several types of advanced, recurrent, and metastatic cancers. It is indicated for patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, and metastatic renal cell carcinoma. Additionally, the therapy is used for specific stages of cervical cancer as well as epithelial ovarian, fallopian tube, or primary peritoneal cancers. Depending on the specific malignancy and treatment line, Jobevne is administered either as a single agent or in combination with chemotherapy or interferon alfa.
How JOBEVNE Works
Jobevne functions by binding to vascular endothelial growth factor (VEGF), preventing it from interacting with its receptors, Flt-1 and KDR, on the surface of endothelial cells. This interaction normally leads to endothelial cell proliferation and the formation of new blood vessels, a process known as angiogenesis. By blocking this pathway, the drug inhibits the growth of microvasculature and the progression of metastatic disease. This mechanism effectively disrupts the blood supply that supports tumor growth and spread.
Details
- Status
- Prescription
- First Approved
- 2025-04-09
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
JOBEVNE Approval History
What JOBEVNE Treats
8 indicationsJOBEVNE is approved for 8 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Metastatic Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
JOBEVNE Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
JOBEVNE is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.
JOBEVNE Competitors
Pro5 other drugs also target VEGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to JOBEVNE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
JOBEVNE FDA Label Details
ProIndications & Usage
FDA Label (PDF)Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treatment. • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : Jobevne is not indicated for adjuvant treatment of colon cancer. • Unresectable, locally advanced, recurrent or ...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.